MNPR enters its August 14 earnings release with one of the more interesting short-covering stories in small-cap biotech right now — a high-conviction short position dissolving rapidly as the NDA clock ticks louder.
The short-covering trend is the headline signal. Short interest has fallen 20% over the past week alone, dropping to roughly 14.5% of free float from a level that was above 23% as recently as a month ago. The direction of travel is unambiguous: over 38% of short shares have been returned in 30 days. That said, at 14.5% of float the position remains meaningfully elevated — this is not a story of shorts exiting cleanly, but of a slow retreat that has left a substantial residual exposure going into a binary catalyst. The ORTEX short score at 70.9 reinforces that framing: still in the upper third of the universe on short pressure, even after a sustained unwind.
The borrow market has loosened in lockstep with the covering. Availability has opened up to 114% — meaning there are now roughly 1.4 shares available to lend for every share currently borrowed — a dramatic reversal from mid-July when availability was as tight as 18%, close to a fully locked lending pool. Cost to borrow has fallen to under 2%, down from a brief spike to 4.4% on July 29 and from the 2.7% range that held through most of July. The loosening borrow tells the same story as the falling SI: the short thesis is being unwound, not pressed.
The Street is aligned bullishly into the print. All eight analysts covering MNPR carry buy-equivalent ratings, with a mean price target of $118 — a slim but positive premium to Tuesday's close of $114.46. HC Wainwright raised its target to $125 on July 22, citing the rolling NDA submission for ALXN1840 in Wilson disease as a positive regulatory signal. Morgan Stanley initiated coverage in January with an Overweight at $115. The bull case centres on the NDA pathway, a differentiated safety profile relative to existing chelation therapies, and potential partnership optionality. Bears point to the standard clinical-stage risks: regulatory timeline slippage, commercial execution uncertainty, and a balance sheet that needs to sustain the company through any approval delay. The price-to-book sits at 8.1x after climbing roughly 0.9x over the past month, reflecting the re-rating the stock has received on the NDA momentum.
Institutional ownership adds an interesting layer. Janus Henderson holds the largest stake at nearly 20% of shares. AstraZeneca holds 7.8% — a strategic position worth watching in the context of any partnership narrative. Deerfield Management added 153,000 shares in Q1, a meaningful commitment from a firm with deep biotech credit expertise. On the insider side, the CEO and COO both received share awards and sold small tranches at $92.59 on June 30 — routine award-and-cover transactions at a price well below current levels, suggesting no negative signal from management.
The earnings history offers a limited read. The last four prints produced moves of -3.5%, +4.9%, -3.1%, and -2.3% on the first day. The five-day window was more mixed, ranging from -5% to +4.6%. Nothing in the history suggests a pattern of outsized reactions. Peer SION crashed nearly 90% over the past week, a reminder of how violently sentiment can swing for small-cap biotechs on binary data. FDMT gained nearly 12% and SLN gained 32% over the same period — the cohort is moving on stock-specific catalysts rather than sector direction, which puts all the weight on whatever MNPR reports Thursday afternoon.
With shorts still covering, borrow conditions easing, and the NDA rolling submission as the central narrative, the August 14 print is less about quarterly financials and more about any update on the ALXN1840 regulatory timeline and cash runway guidance.
See the live data behind this article on ORTEX.
Open MNPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
